Ephedrine produces modest short-term fat loss and a small rise in energy use, strongest alongside caffeine and a calorie-controlled diet; it also blunts hunger and may help preserve muscle. Benefits are small and fade within months, while faster heartbeat, raised blood pressure, restlessness, and poor sleep are common and, rarely, serious. Long-term effects are untested. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting blood pressure | ~110–125 / 70–80 mmHg | Ephedrine's core cardiovascular risk |
| Resting heart rate | ~55–70 beats per minute | Direct marker of cardiac stimulation |
| Thyroid-stimulating hormone (TSH) | ~0.5–2.5 mIU/L | Rules out overactive thyroid, a contraindication |
| Electrocardiogram (ECG) | Normal sinus rhythm | Screens for arrhythmia risk before stimulant use |
| Fasting glucose and lipid panel | Glucose ~70–90 mg/dL; favorable HDL/LDL/triglycerides | Tracks metabolic response and lipid changes |
| Body weight and waist circumference | Individualized downward trend | Primary efficacy endpoint |
| Serum potassium | ~4.0–4.5 mmol/L | Stimulant and diuretic-like effects and co-drugs can lower it |
Cadence: Blood pressure and heart rate before the first dose, again within the first 1–2 weeks, then roughly monthly while use continues